Силибор

Selected form

Silymarin

Method of action: Antioxidant, Hepatoprotective

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Силибор

What is Silibor? General Information on the Drug

Silibor is a medicinal product primarily used to support and protect the function of the liver, and is classified as a hepatoprotective agent. It is a plant-derived formulation intended to reinforce liver cell structure and function.

Quick Facts about Silibor
Active ingredient	Silymarin (INN)
Form	Tablets (Oral administration)
Pharmacological class	Hepatoprotective agent
Common use	Supportive therapy for liver health
Origin	Plant-derived (Milk Thistle)

Silibor: Definition and Pharmacological Class

Silibor is formally defined as a medicine that falls under the high-level pharmacological category of hepatoprotective agents. This classification signifies its main therapeutic role: to help guard liver cells against harmful influences. The general purpose of Silibor is to provide supportive care for the liver when it is under metabolic stress, such as during periods of poor diet or recovery. The active component, Silymarin, has an established use in various liver disorders.

Composition and Origin: Milk Thistle Extract

The active component in Silibor is the International Nonproprietary Name (INN) substance Silymarin. Silymarin is a standardized mixture of beneficial molecules, primarily flavonolignans, which are concentrated and extracted from the seeds of the Milk Thistle (Silybum marianum) plant. This plant-derived origin is a defining characteristic of the medicine. Milk Thistle fruit is categorized as a traditional herbal medicinal product for relieving symptoms associated with digestive disorders, including the feeling of fullness and sluggish digestion. This traditional use supports the use of Silymarin for general gastrointestinal and liver comfort.

Dosage Form and Core Action

Silibor is typically manufactured in the form of oral tablets or capsules, which determine its route of administration. The core action of Silymarin on the liver is its ability to exert a membrane-stabilizing and antioxidant effect. By neutralizing damaging free radicals and helping to reinforce the outer membrane of liver cells, Silibor supports the liver's natural processes of regeneration and protects it from the entry of certain toxins.

What side effects are possible with Силибор?

Possible Side Effects and Safety Information

Силибор, which contains the active substance silymarin, is generally characterized by low toxicity and is typically well-tolerated, even with prolonged administration at recommended doses. The adverse reactions observed are infrequent, and no serious adverse events have been widely reported in clinical use.

Documented Adverse Reactions

Adverse drug reactions are typically classified according to their frequency, with most reported events falling into the Rare or Very Rare categories:

Rare (geq1/10,000 to <1/1,000): Gastrointestinal disorders, such as a mild laxative effect, may occur.
Very Rare (<1/10,000): Hypersensitivity reactions (allergic reactions), which may manifest as skin rash or dyspnoea (shortness of breath), have been observed.

System Organ Class	Observed Adverse Reaction
Gastrointestinal disorders	Mild laxative effect, abdominal discomfort
Immune system disorders	Hypersensitivity reaction
Skin and subcutaneous tissue disorders	Rash, itching
Respiratory, thoracic, and mediastinal disorders	Dyspnoea (Very Rare)

Safety Considerations and Restrictions

Population-Specific Warnings:

Pregnancy and Lactation: As a precautionary measure due to insufficient safety data, the use of silymarin is preferably avoided during pregnancy and breastfeeding.
Pediatric Use: The safety and efficacy of this preparation have not been established in children, and its use is generally not recommended for this population.

Cautionary Notes:

Treatment does not replace the necessity of abstaining from the cause of liver damage (e.g., alcohol).
If icterus (jaundice—a light to dark yellow tinge of the skin or eyes) occurs, professional medical consultation is required.

Overdose and Emergency Response

The official regulatory profile for Silibor (Silymarin) overdosage is defined by the limited observations recorded in clinical experience, establishing the basis for mandated emergency actions.

Overdose scope

Feature	Official Regulatory Statement
Documented overdose presentations	Signs or symptoms of overdosage or poisoning have not hitherto been observed.
Physiological systems affected	Amplification of known undesirable effects, such as mild laxative effects, rash, or breathing difficulties (dyspnoea).
Emergency-response statements	Treatment for overdosage, if necessary, is limited to symptomatic measures.
When immediate medical help is required	Urgent medical attention should be sought if overdosage is suspected or if the known undesirable effects are amplified to a concerning or severe degree.

Overdose classifications (high-level)

Feature	Official Regulatory Statement
Severity classification	Not formally classified by severity; regulatory documents note that specific symptoms have not hitherto been observed.
Overdose-context constraints	A special antidote is not known for Silibor overdosage.

Resulting overdose structure

Official overdose statements:

Regulatory documentation states that signs or symptoms of overdosage or poisoning with Silibor have not been observed in clinical experience.
The primary documented concern is the potential for known mild side effects to become amplified.
Treatment is limited to symptomatic measures as a special antidote is not known.

Connection to the overall overdose profile (2–4 sentences):

The regulatory documentation defines the overdose profile of Silibor around the non-observance of specific acute poisoning signs, which guides the required emergency actions. Consequently, intervention is restricted to symptomatic measures, and the condition for seeking urgent medical attention is tied to the severe amplification of any existing undesirable effects.

Therapeutic Uses of Силибор

What Silibor Treats: Main Uses and Benefits

Silibor is commonly used as a supportive agent for patients managing conditions involving inflammatory or irritative processes of the liver, which may include non-alcoholic fatty liver disease (NAFLD) and stable chronic hepatitis. The key ingredient is used to support liver function and relieve associated digestive symptoms. This support is also relevant during phases when the liver is under heightened metabolic stress, such as following exposure to certain toxins, and may assist with maintaining functional stability of the liver.

Silibor is relevant for easing symptom clusters related to organ-specific functional stress. Indications for use include supportive management of chronic hepatitis, NAFLD, and relief from digestive disturbances. The medication is helpful in situations where symptoms of sluggish digestion or heaviness in the right upper quadrant create noticeable physiological strain.

“The support provided is relevant for easing the overall symptom burden.”

Quick Fact: Relief for Digestive Discomfort

Silibor may assist with managing symptoms of post-meal fullness and bloating linked to liver strain, supporting patients during episodes of heightened discomfort.

Regulatory References

European Medicines Agency (EMA) HMPC conclusions

Eligibility and Restrictions for Use

Official Eligibility Rules for Silibor (Silymarin)

The criteria defining who can and cannot use Silibor are strictly based on established regulatory documentation, focusing on population-specific restrictions and contraindications, rather than general safety or efficacy data.

Eligibility Classification	Population Group & Restriction
Contraindicated	Individuals with known hypersensitivity to the active substance Silymarin, any excipients, or plants of the Asteraceae (Compositae) family, such as ragweed or daisies. Some regulatory labels also cite severe bile duct issues or advanced liver failure as contraindications.
Not Recommended	Children and adolescents under 18 years of age. Use in this group is restricted due to insufficient data to establish safety and efficacy.
Not Recommended	Women who are pregnant or breastfeeding. This restriction is advised as a precautionary measure due to a lack of sufficient reliable data regarding safety during these physiological states.

Condition-Specific Rules:

Use is generally permitted for adults (18 years and older) unless any contraindications exist. Caution is advised for patients with hormone-sensitive conditions (e.g., specific cancers or fibroids), given the potential for the extract to exert mild estrogenic effects. Patients with conditions like Diabetes Mellitus or who develop jaundice must seek specialized medical assessment, as the medicine's supportive role is not a replacement for necessary clinical treatment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interactions involving Silibor (Silymarin) are officially documented in regulatory sources and primarily involve pharmacokinetic modifications to other medicines. This information is critical for understanding combination therapy constraints.

Pharmacokinetic and Exposure Effects

Silibor has the potential to modulate the activity of drug-metabolizing Cytochrome P450 (CYP) enzymes, specifically CYP2C9, and the drug transporter P-glycoprotein (P-gp). This can lead to altered systemic exposure (increased plasma levels) of co-administered medicines that are substrates for these pathways.

Officially Documented Interactions:

Interacting Substance	Interaction Type	Regulatory Recommendation
Simeprevir	Increased Exposure (Plasma Levels)	Avoid concurrent use
Raloxifene	Potential for Increased Exposure	Monitor/Use with Caution
Warfarin, Diazepam	CYP2C9/P-gp Substrates	Potential for altered levels

Mechanism of Action

The pharmacological action of Silibor is exerted through three main mechanistic domains. Firstly, the compound exhibits antioxidant activity by scavenging free radicals and modulating the levels of endogenous antioxidants, specifically glutathione and enzymes such as superoxide dismutase. This activity influences the cellular redox status and helps maintain the structural integrity of cell membranes and intracellular components. Secondly, Silibor modulates signal transduction pathways by inhibiting the NF-κB pathway and influencing the release of pro-inflammatory cytokines, including TNF- alpha. This action modulates the downstream effects of inflammatory signaling cascades and influences systemic inflammatory parameters. Lastly, the compound alters the structure of the hepatocyte external membrane, which modulates cellular permeability to xenobiotics. Furthermore, it regulates intracellular processes by stimulating the activity of Phase I and Phase II detoxification enzymes. This mechanism influences pathway regulation and contributes to the modulation of xenobiotic metabolism and elimination processes within the targeted tissue.

Dosage and Administration Information

How to use Силибор: Administration Principles

Silibor (Silymarin) is administered exclusively via the oral route, typically formulated as a 140 mg tablet or capsule. The standard adult regimen requires a total daily dose of 420 mg, which is achieved by adhering to a three times daily (TID) frequency, taking one 140 mg unit per dose. This divided dosing pattern is designed to support consistent therapeutic levels.

Administration Context and Duration

Each unit dose must be swallowed whole with liquid. While the primary instruction specifies frequency, the medication is commonly administered with or immediately following meals to support optimal absorption properties. The duration of therapy is not defined by short cycles, but is intended for long-term supportive use consistent with its application in chronic conditions.

Population and Procedural Structure

The usage guidelines apply to adults. Safety and efficacy of Silymarin are not established for use in the pediatric population, which limits its administration scope. The core administration protocol is procedural: one unit dose is taken three times per day, ensuring the total daily intake of 420 mg is met. This structured approach, based on specific dosing and timing, defines the principles for using this medicine.

Recent Clinical Evidence

Silibor: Recent Clinical Evidence

Evidence for Supportive Management of Chronic Hepatitis

Research has explored the use of Silibor's main ingredient, Silymarin, in patient groups managing stable chronic hepatitis, which includes persistent, long-term inflammation of the liver from various causes. The main research design used in this area is the Randomized Controlled Trial (RCT), a common study type. These trials, along with subsequent reviews, were used in research examining clinical markers of liver function.

In these studies, researchers monitored changes in key liver enzyme levels (like ALT and AST) over time. Reported findings concerning the specific changes in liver enzyme levels were variable and inconsistent across the research. The overall body of evidence describes patterns measured during the study period, but does not definitively indicate uniform outcomes.

What remains uncertain are the patterns of long-term clinical outcomes, such as preventing the progression to end-stage liver disease or tracking changes in overall survival. Follow-up durations were limited, typically lasting up to a year, meaning that long-term effects are not fully established.

Evidence in Non-Alcoholic Fatty Liver Disease (NAFLD) Support

Silibor's active component was studied in research contexts involving Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH). The trials monitored outcomes related to systemic or functional imbalance associated with NAFLD. Studies focused on both liver enzyme levels and metabolic markers. Findings for these changes were mixed, and comparative evidence against current therapeutic options is limited.

Evidence for Relief of Digestive Symptoms

The research basis exploring Silibor's ingredient in relation to digestive discomfort, such as feelings of post-meal fullness or sluggish digestion, relies primarily on long-standing Traditional Use summaries. The coarse evidence level for this indication is considered low because supporting research often consists of small studies, and there is a lack of large, high-quality, placebo-controlled trials.

What is Still Uncertain About Silibor Research

Research provides context but not individual predictions. Key areas where research is needed include addressing the Inconsistency in Findings across different clinical trials, resolving the Lack of Long-Term Data regarding outcomes like progression of liver disease, and improving the Subgroup Findings for populations such as children or patients with advanced disease.

Frequently Asked Questions (FAQ)

Common questions about Силибор (FAQ)

Q: How quickly should I expect to notice any effects from Силибор?

Official information does not specify a timeline for when effects are generally observed in patients. The product is intended for supportive, long-term use consistent with the management of chronic conditions. Questions regarding the expected duration of use and follow-up should be directed to a healthcare provider.

Q: Are there any food restrictions I need to know about when taking Силибор?

Official product information does not list major restrictions for specific foods while using Силибор. The labeling indicates the medicine may be taken with or without food. However, it has commonly been administered with or immediately following meals.

Q: Is the evidence for Силибор's use considered strong or preliminary by researchers?

The regulatory assessment often acknowledges the product’s long history of traditional use. However, the European Medicines Agency notes that current clinical trials have provided insufficient evidence to establish strong, uniform conclusions regarding efficacy.

Q: Is there any research on Силибор's use in children or teenagers?

The official product documentation states that the safety and efficacy of the preparation have not been established in children and adolescents. Due to this lack of established data, use of the product is generally not recommended outside of the adult population (18 years and older).

Q: If I have a kidney issue, what do official sources say about using Силибор?

Official pharmacological information notes that data regarding the product's action and safety in patients with renal insufficiency (kidney issues) is currently absent or lacking. The consideration of using the product for a patient with a pre-existing kidney condition falls under professional medical guidance.

Q: Do any official sources mention how to handle an overdose of Силибор?

A specific antidote for the active substance is not currently known or listed in regulatory documents. Treatment in the event of an overdose is generally described as the application of symptomatic measures to manage any resulting effects. Professional medical assistance is required if an overdose is suspected.

Q: What is the main difference between Силибор and other common liver supplements?

Силибор's core active component, Silymarin, is a well-defined, plant-derived substance extracted from milk thistle. Its established actions are described in official literature as providing antioxidant and membrane-stabilizing effects on liver cells, defining its supportive role.

Q: What kind of studies have been done on Силибор?

The research base includes clinical investigations such as Randomized Controlled Trials (RCTs), which have typically focused on measuring changes in markers like liver enzyme levels. Regulatory evaluations also consider extensive summaries of the product’s long history of traditional use over many decades.

Q: Is Силибор approved in the U.S. or Europe?

The classification varies by region. In the European Union, the product is often covered by an EMA Herbal Monograph for traditional medicinal use. In the United States, the Food and Drug Administration (FDA) typically regulates similar products as dietary supplements, rather than as prescription or non-prescription drugs.

Q: Is it okay to take Силибор with my daily vitamin or mineral supplement?

The official product labeling for the active component generally states that no interactions with other non-prescription medicinal products are known. The potential for interactions with high-dose supplements or specific combinations is information that falls under professional assessment.

Q: Is there a patient information leaflet available for Силибор, and where can I find it?

Regulatory bodies worldwide advise that the full, legally required instructions for use and comprehensive safety information are contained in the patient information leaflet (PIL). This leaflet is always provided inside the medicine's original packaging.

Q: Is the drug ever used for purposes other than those officially listed?

Official guidance in the United States clarifies that the product is not intended to diagnose, treat, cure, or prevent any disease beyond its defined supportive role. Use for purposes other than those officially listed in regulatory documents is outside the scope of its authorized labeling.

Q: Why do some people mistakenly believe Силибор cures certain diseases?

This type of misunderstanding can occur when the product's role as supportive therapy is misinterpreted. Regulatory classifications clarify that the product is intended to support the body's natural processes and is not approved to diagnose, treat, cure, or prevent a specific disease.

How should Силибор be stored and disposed of?

The storage and disposal of Силибор (Silibor) must strictly follow the conditions defined in official regulatory documents to maintain its labeled stability.

Storage Element	Required Condition (Official Labeling)
Temperature	Store at a temperature not exceeding 25°C (Controlled Room Temperature).
Protection	Must be kept in a dry place and protected from light.
Packaging	Storage is required in the original container/packaging.

All regulatory labeling mandates that the medicine be kept out of the reach of children. The product must not be used beyond its stated expiration date. Disposal of any unused or expired tablets should be conducted according to local regulatory guidelines for pharmaceutical waste, which typically advise against disposal via household waste or water systems.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.